Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-01 | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F
(Director) |
S | Common Stock | D | 100 | $957.78 - $965.35 | $96,249 |
| 2024-02-26 | REGENERON PHARMACEUTICALS, INC. | LAROSA JOSEPH J
(EVP General Counsel and Secret) |
S | Common Stock | D | 1000 | $990.00 - $990.00 | $990,000 |
| 2024-02-26 | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L
(Director) |
S | Common Stock | D | 854 | $979.25 - $979.25 | $836,279 |
| 2024-02-26 | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L
(Director) |
M | Common Stock | A | 854 | $391.92 - $391.92 | $334,699 |
| 2024-02-22 | REGENERON PHARMACEUTICALS, INC. | LAROSA JOSEPH J
(EVP General Counsel and Secret) |
S | Common Stock | D | 1000 | $967.65 - $967.65 | $967,650 |
| 2024-02-22 | REGENERON PHARMACEUTICALS, INC. | SING GEORGE L
(Director) |
S | Common Stock | D | 3500 | $960.00 - $985.00 | $3,387,500 |
| 2024-02-22 | REGENERON PHARMACEUTICALS, INC. | SING GEORGE L
(Director) |
M | Common Stock | A | 3500 | $413.33 - $413.33 | $1,446,655 |
| 2024-02-02 | REGENERON PHARMACEUTICALS, INC. | STAHL NEIL
(EVP Research and Development) |
M | Common Stock | A | 30750 | $399.66 - $399.66 | $12,289,545 |
| 2024-02-02 | REGENERON PHARMACEUTICALS, INC. | STAHL NEIL
(EVP Research and Development) |
F | Common Stock | D | 22713 | $956.65 - $956.65 | $21,728,391 |
| 2024-02-02 | REGENERON PHARMACEUTICALS, INC. | Landry Robert E
(EVP Finance CFO) |
M | Common Stock | A | 400 | $378.98 - $378.98 | $151,592 |
| 2024-02-02 | REGENERON PHARMACEUTICALS, INC. | Landry Robert E
(EVP Finance CFO) |
F | Common Stock | D | 281 | $956.65 - $956.65 | $268,818 |
| 2024-02-05 | REGENERON PHARMACEUTICALS, INC. | McCourt Marion
(EVP Commercial) |
S | Common Stock | D | 1000 | $934.71 - $934.71 | $934,710 |
| 2024-02-01 | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F
(Director) |
S | Common Stock | D | 100 | $939.53 - $963.73 | $95,412 |
| 2024-01-30 | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L
(Director) |
S | Common Stock | D | 827 | $959.00 - $959.00 | $793,093 |
| 2024-01-30 | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L
(Director) |
M | Common Stock | A | 827 | $380.95 - $380.95 | $315,045 |
| 2024-01-23 | REGENERON PHARMACEUTICALS, INC. | GOLDSTEIN JOSEPH L
(Director) |
S | Common Stock | D | 2707 | $950.00 - $950.00 | $2,571,650 |
| 2024-01-23 | REGENERON PHARMACEUTICALS, INC. | GOLDSTEIN JOSEPH L
(Director) |
M | Common Stock | A | 2707 | $625.60 - $625.60 | $1,693,499 |
| 2024-01-23 | REGENERON PHARMACEUTICALS, INC. | Fenimore Christop...
(SVP Controller) |
M | Common Stock | A | 10000 | $399.66 - $555.67 | $4,776,650 |
| 2024-01-23 | REGENERON PHARMACEUTICALS, INC. | Fenimore Christop...
(SVP Controller) |
F | Common Stock | D | 7569 | $948.50 - $948.50 | $7,179,196 |
| 2024-01-23 | REGENERON PHARMACEUTICALS, INC. | Landry Robert E
(EVP Finance CFO) |
M | Common Stock | A | 1600 | $378.98 - $378.98 | $606,368 |
| 2024-01-23 | REGENERON PHARMACEUTICALS, INC. | Landry Robert E
(EVP Finance CFO) |
F | Common Stock | D | 1128 | $948.50 - $951.26 | $1,070,879 |
| 2024-01-02 | REGENERON PHARMACEUTICALS, INC. | Zoghbi Huda Y
(Director) |
S | Common Stock | D | 1117 | $900.00 - $900.00 | $1,005,300 |
| 2024-01-02 | REGENERON PHARMACEUTICALS, INC. | Zoghbi Huda Y
(Director) |
M | Common Stock | A | 1117 | $391.92 - $391.92 | $437,774 |
| 2024-01-03 | REGENERON PHARMACEUTICALS, INC. | Fenimore Christop...
(SVP Controller) |
F | Common Stock | D | 7512 | $912.30 - $912.30 | $6,853,196 |
| 2024-01-02 | REGENERON PHARMACEUTICALS, INC. | Zoghbi Huda Y
(Director) |
A | Common Stock | A | 135 | $0.00 - $0.00 | $0 |
| 2023-12-13 | REGENERON PHARMACEUTICALS, INC. | Bassler Bonnie L
(Director) |
S | Common Stock | D | 610 | $870.00 - $870.00 | $530,700 |
| 2023-12-13 | REGENERON PHARMACEUTICALS, INC. | Landry Robert E
(EVP Finance CFO) |
M | Common Stock | A | 1000 | $378.98 - $378.98 | $378,980 |
| 2023-12-12 | REGENERON PHARMACEUTICALS, INC. | McCourt Marion
(EVP Commercial) |
F | Common Stock | D | 5105 | $856.71 - $856.71 | $4,373,504 |
| 2023-12-11 | REGENERON PHARMACEUTICALS, INC. | YANCOPOULOS GEORGE
(Bd. Co-Chair, President & CSO) |
F | Common Stock | D | 12841 | $844.09 - $844.09 | $10,838,959 |
| 2023-12-08 | REGENERON PHARMACEUTICALS, INC. | Fenimore Christop...
(SVP Controller) |
F | Common Stock | D | 2010 | $843.79 - $844.09 | $1,696,477 |
| 2023-12-08 | REGENERON PHARMACEUTICALS, INC. | Fenimore Christop...
(SVP Controller) |
A | Common Stock | A | 2370 | $0.00 - $0.00 | $0 |
| 2023-12-05 | REGENERON PHARMACEUTICALS, INC. | MURPHY ANDREW J
(EVP Research) |
S | Common Stock | D | 6536 | $810.38 - $821.46 | $5,342,783 |
| 2023-12-04 | REGENERON PHARMACEUTICALS, INC. | MURPHY ANDREW J
(EVP Research) |
M | Common Stock | A | 20000 | $270.43 - $270.43 | $5,408,600 |
| 2023-12-04 | REGENERON PHARMACEUTICALS, INC. | MURPHY ANDREW J
(EVP Research) |
F | Common Stock | D | 13464 | $813.58 - $813.58 | $10,954,041 |
| 2023-11-07 | REGENERON PHARMACEUTICALS, INC. | RYAN ARTHUR F
(Director) |
S | Common Stock | D | 100 | $824.59 - $838.46 | $82,787 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |